-
Bayer Brings External Innovation Inside, With Guardrails9/1/2022
Can Bayer’s “arm’s-length model” for acquired companies help turn the century-and-a-half year-old Big Pharma into a leader in gene and cell therapy, and a top 10 player in oncology?
-
Alnylam’s Challenge: Scaling Up And Moving Beyond The Liver8/1/2022
Alnylam CEO Yvonne Greenstreet talks about what’s next for the company, including a transition into larger therapeutic areas and patient populations, and describes her own journey to the CEO role.
-
Representation Matters. Location Does Too.8/1/2022
Representation at the top of any profession, whether jurisprudence or biotechnology, works as an accelerator for younger generations to follow.
-
KemPharm: Converting FDA Complete Response Letters Into New Opportunities8/1/2022
KemPharm’s experience in reworking product NDAs following FDA Complete Response Letters has created a unique capability within the company, and helped it move to acquire a potentially valuable asset from distressed biopharma Orphazyme.
-
A Network And Pivot Model For Success In Cancer Drug Development7/1/2022
When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people.
-
Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma’s CEO Ron Cooper7/1/2022
Albireo Pharma CEO Ron Cooper discusses the company’s three approaches to commercializing orphan drugs globally, and how to go from topline data to regulatory filing in 70 days.
-
Scouting Turbulence For Opportunity7/1/2022
With bad news in the headlines at home and globally, and a seesawing public market capable of wiping years of value from company books almost overnight, it can be difficult to remain focused on the bread-and-butter tasks that keep a company afloat.
-
Leveling Up By Challenging Assumptions6/1/2022
An outspoken champion of gender equity and diversity in the workplace, Arcellx CEO Rami Elghandour aims to put the company’s controllable CAR-T therapies on the cover of Time magazine.
-
From Summer Stroll To Summer Hustle6/1/2022
As news reporter covering the biopharmaceutical industry in the early aughts, the summer months could present a different kind of challenge.